Ilon Liu

Dr. med.

In vivo characterization of Px IV, a novel glutathione peroxidase-type enzyme, in African trypanosomes.

Fach: Biochemie

Doktormutter: Prof. Dr. rer. nat. Luise Krauth-Siegel

T. brucei subspecies are the causative agent of human African sleeping sickness and Nagana cattle disease. Based on their specific trypanothione-tryparedoxin system, hydroperoxide detoxification is achieved by 2-Cys-peroxiredoxins (TXNPx) and glutathione peroxidase-type enzymes (Px). So far, the two cytosolic Px I-II and the mitochondrial Px III have been characterized in bloodstream *T. brucei*.

In this thesis, the role of a fourth, distantly related glutathione peroxidase type enzyme, Px IV, was studied.

As specific antibodies against the protein were not available, vectors that allow the inducible expression of N- and C-terminally myc_6 -tagged versions of the protein (pRPa^{ix6Mx}_N-myc_6_px IV and pRPa^{ix6Mx}_px IV_C-myc_6) were cloned and bloodstream *T. b. brucei* were transfected with the constructs. Immunofluorescence analyses of different clones revealed a mitochondrial localization of Px IV. The C-terminally tagged protein clearly co-localized with the mitochondrial marker MitoTrackerTM, while the N-terminally tagged version co-localized with the cytosolic markers TR and TXNPx. This contrasts with TcGPXII, an orthologue of Px IV in *T. cruzi*, described to be an ER resident protein. A co-localization with the ER marker BiP was excluded for both the N- and C-terminally myc_6-tagged *T. brucei* Px IV due to the significantly lower Pearson correlation coefficient (R_r) for BiP compared to the ones for the respective mitochondrial or cytosolic markers. Thus, Px IV is likely to be a mitochondrial protein possessing an N-terminal mitochondrial targeting signal.

To elucidate if Px IV is essential, the mRNA of px IV was depleted in four different bloodstream RNAi cell lines after respective transfection with constructs derived from the

pRPa vector. The sizes of the mRNA of *px* IV deriving from *trans*-splicing were determined. cDNA analysis using a spliced leader primer and a reverse internal primer as well as a forward internal primer and an Oligo(T) primer, respectively, revealed two possible *px* IV mRNAs of 628 bases and 978 bases. These two forms corresponded to bands in the Northern blot. Both were not downregulated after RNAi, suggesting that the RNAi was not efficient. A high throughput RNAi approach had indicated essentiality of Px IV in bloodstream parasites using RNAi constructs that differed from those used in this work. Overexpression of the myc₆-tagged versions likewise did not reveal a difference in proliferation compared to WT parasites.

Because of the insufficient mRNA depletion, cloning of *px* IV knockout constructs was carried out. As a first step for the generation of (conditional) knockout cell lines, the vectors pHD 1747_*px* IV (puromycin resistance) and pHD 1748_*px* IV (blasticidin resistance) were generated and WT bloodstream *T. b. brucei* cells as well as Px IV overexpressing cells were successively transfected with both vectors.

This thesis adds a new potential candidate to the antioxidant defense mechanisms in the mitochondrion of *T. brucei*, so far consisting of a 2-Cys-peroxiredoxin and Px III, another non-selenium glutathione peroxidase type enzyme. Since both peroxidases proved to be not essential in bloodstream *T. brucei*, the role of Px IV in the mitochondrion of trypanosomatids will be of high interest.